0.757
0.01 (1.15%)
| Previous Close | 0.748 |
| Open | 0.725 |
| Volume | 9,643 |
| Avg. Volume (3M) | 1,042,366 |
| Market Cap | 8,103,988 |
| Price / Sales | 59.33 |
| Price / Book | 0.720 |
| 52 Weeks Range |
| Operating Margin (TTM) | -2,518.17% |
| Diluted EPS (TTM) | -0.350 |
| Quarterly Revenue Growth (YOY) | 56.80% |
| Total Debt/Equity (MRQ) | 25.43% |
| Current Ratio (MRQ) | 0.080 |
| Operating Cash Flow (TTM) | -1.07 M |
| Return on Assets (TTM) | -8.04% |
| Return on Equity (TTM) | -21.00% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Mixed |
| Drug Manufacturers - Specialty & Generic (Global) | Mixed | Mixed | |
| Stock | Gelteq Limited | - | - |
AIStockmoo Score
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.13 |
|
Gelteq Ltd is a clinical and science-based company focused on developing and commercializing white label gel-based delivery solutions for prescription drugs, nutraceuticals, pet care and other products, preserving the simplicity, accessibility, and efficacy of oral delivery. Its principal products are edible gels and their application in gel-based dosage forms across pets, sports, pharmaceutical, over-the-counter, and nutraceutical categories, leveraging its patent pending multiple ingredient dosage forms. The company develops and tests gel-based delivery systems for humans and pets and focuses on out-licensing its technology to companies to create products that can be manufactured and sold, while continuing to manufacture existing products under license on a white label basis. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Growth |
| % Held by Insiders | 60.36% |
| % Held by Institutions | 1.11% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Wedbush Securities Inc | 31 Dec 2025 | 20,000 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |